Affiliation:
1. zhejiang university of technology
Abstract
Abstract
Background: Biliary tract cancer (BTC) remains one of the rare but most devastating cancer diseases, with a rising global burden. The increasing mortality and morbidity trends have indicated the need for improved interventions for effective treatment for all the BTC subtypes. Henc, there has been proposals for use of combined chemotherapy and immunotherapy.
Methods and Results: The main research question was “How effective is Chemotherapy-Immunotherapy combination compared to Chemotherapy and Immunotherapy alone in treating Biliary Tract Cancer?” The systematic review followed the mixed-method research design based on the PRISMA guidelines. This systematic review focused on studies published between 2022 and 2023. The results showed that both chemotherapy combined with immunotherapy and monotherapies are effective in treating BTC.
Conclusions: Chemotherapy combined with immunotherapy as well as monotherapies are effective and safer.
Publisher
Research Square Platform LLC
Reference31 articles.
1. Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial;Jin S;International Journal of Cancer,2023
2. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma;Du J;Frontiers in Immunology,2023
3. Zhang, S.Z., Zhang, L. and Xie, L., 2022. Cancer Burden in China during 1990–2019: Analysis of the Global Burden of Disease. BioMed Research International, 2, pp.1–12.
4. Precision medicine in cholangiocarcinoma: past, present, and future;Cheng CY;Life,2022
5. Evolving role of immunotherapy in advanced biliary tract cancers;Kang S;Cancers,2022